MacuSight 
Welcome,         Profile    Billing    Logout  
 1 Product   1 Disease  1 Product   2 Trials   106 News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Opsiria (sirolimus) / Santen
2019-003638-18: A study to see how safe and how well an investigational medicinal product will work to treat active non-infectious uveitis of the posterior segment of the eye. Uno studio per vedere quanto è sicuro e quanto funziona un medicinale sperimentale per trattare l'uveite non infettiva attiva del segmento posteriore dell'occhio.

Not yet recruiting
3
200
Europe
Opsiria, Predni-POS 1% sospensione oftalmica, Pred Forte 1% collirio sospensione, Prednisolone acetato sospensione ad uso oftalmico USP, 1%, [DE-109], [NA], Solution for injection, Eye drops, suspension, Predni-POS 1% sospensione oftalmica, Pred Forte 1% collirio sospensione, Prednisolone acetato sospensione ad uso oftalmico USP, 1%
SANTEN INCORPORATED, Santen Incorporated
Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. uveite non infettiva attiva del segmento posteriore dell'occhio, Non-Infectious posterior Uveitis. uveite non infettiva posteriore, Body processes [G] - Ocular Physiological Phenomena [G14]
 
 
2022-000174-25: Phase 2a, Random, double masked, Placebo-controlled, side by side group, multiple center study evaluating the success and safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% compared with Placebo in Subjects with Fuchs endothelial Corneal Dystrophy (FECD)

Not yet recruiting
2
80
Europe
STN1010904 Ophthalmic Suspension, STN1010904 (DE-109D), Eye drops
SANTEN INCORPORATED, Santen Inc.
Fuchs Endothelial Corneal Dystrophy (FECD) Dystrophie cornéenne endothéliale de Fuchs (FECD), Fuchs Endothelial Corneal Dystrophy (FECD) Dystrophie cornéenne endothéliale de Fuchs (FECD), Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
SAVE-2, NCT01280669: Intravitreal Sirolimus as Therapeutic Approach to Uveitis

Checkmark ARVO 2015: SAVE-2
Apr 2015 - Apr 2015: ARVO 2015: SAVE-2
Withdrawn
2
30
US
Intravitreal injection 440mcg, Low-dose, Monthly, Intravitreal injection of sirolimus 880mcg, High-dose, Bi-monthly
Stanford University, Santen Inc.
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
09/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Opsiria (sirolimus) / Santen
2019-003638-18: A study to see how safe and how well an investigational medicinal product will work to treat active non-infectious uveitis of the posterior segment of the eye. Uno studio per vedere quanto è sicuro e quanto funziona un medicinale sperimentale per trattare l'uveite non infettiva attiva del segmento posteriore dell'occhio.

Not yet recruiting
3
200
Europe
Opsiria, Predni-POS 1% sospensione oftalmica, Pred Forte 1% collirio sospensione, Prednisolone acetato sospensione ad uso oftalmico USP, 1%, [DE-109], [NA], Solution for injection, Eye drops, suspension, Predni-POS 1% sospensione oftalmica, Pred Forte 1% collirio sospensione, Prednisolone acetato sospensione ad uso oftalmico USP, 1%
SANTEN INCORPORATED, Santen Incorporated
Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. uveite non infettiva attiva del segmento posteriore dell'occhio, Non-Infectious posterior Uveitis. uveite non infettiva posteriore, Body processes [G] - Ocular Physiological Phenomena [G14]
 
 
2022-000174-25: Phase 2a, Random, double masked, Placebo-controlled, side by side group, multiple center study evaluating the success and safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% compared with Placebo in Subjects with Fuchs endothelial Corneal Dystrophy (FECD)

Not yet recruiting
2
80
Europe
STN1010904 Ophthalmic Suspension, STN1010904 (DE-109D), Eye drops
SANTEN INCORPORATED, Santen Inc.
Fuchs Endothelial Corneal Dystrophy (FECD) Dystrophie cornéenne endothéliale de Fuchs (FECD), Fuchs Endothelial Corneal Dystrophy (FECD) Dystrophie cornéenne endothéliale de Fuchs (FECD), Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
SAVE-2, NCT01280669: Intravitreal Sirolimus as Therapeutic Approach to Uveitis

Checkmark ARVO 2015: SAVE-2
Apr 2015 - Apr 2015: ARVO 2015: SAVE-2
Withdrawn
2
30
US
Intravitreal injection 440mcg, Low-dose, Monthly, Intravitreal injection of sirolimus 880mcg, High-dose, Bi-monthly
Stanford University, Santen Inc.
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
09/24
12/24

Download Options